Brand identity is fundamental to the pharmaceutical sector, yet a disconnect persists in how trademark laws protect these brands 🔗️ compared to other industries. Courts frequently apply a legal presumption known as the "heightened level of attention," assuming consumers exercise exceptional scrutiny when purchasing health-related products. While intended to ensure public safety, this assumption creates a paradoxical barrier to enforcement, often resulting in weaker protection for pharmaceutical marks than anticipated and complicating efforts to prevent brand dilution and counterfeiting.
The EU Perspective: Context Matters Less Than Health Concerns
A recent case before the General Court of the European Union (T-591/24) illustrates this tension. Sandoz opposed the registration of "ARYUNA" by citing the prior mark "ARMUNIA." Initially, the opposition failed because the European Union Intellectual Property Office (EUIPO) applied the standard rule: consumers buying pharmaceuticals are presumed to be highly attentive and thus able to distinguish between "ARYUNA" and "ARMUNIA."
Sandoz argued that this presumption is flawed for certain over-the-counter (OTC) items, such as herbal tinctures, which are often purchased quickly in retail settings without medical supervision. In these contexts, buying behavior resembles ordinary grocery shopping rather than the careful selection of prescription drugs. Sandoz contended that because health risks are involved, the threshold for proving confusion 🔗️ should be lower, not higher.
The General Court rejected this argument on July 1, 2026, reaffirming that regardless of where OTC pharmaceuticals are sold, their nature affects human health. Consequently, consumers are expected to exercise a high level of care. The court drew a sharp line between trademark law 🔗️ and regulatory public health laws. While regulators manage safety, trademark law operates on the presumption that consumers will naturally pay more attention to anything labeled as medicine. This creates a rigid framework where slight similarities in marks are often deemed non-confusing simply because the courts assume the buyer is being cautious.
The Greek Paradox: Linguistic Nuances and Reputed Marks
This dynamic becomes more complex in national jurisdictions such as Greece, particularly regarding reputed marks and cross-class protection. Recent administrative court decisions involving PepsiCo highlight how local language peculiarities can undermine trademark strength 🔗️.
PepsiCo sought to invalidate a Greek figurative mark featuring the word "PEPSI" for dietetic products in Class 5 (pharmaceuticals). The initial ruling by the Trademark Office favored the registrant, citing differences in goods and marks. However, PepsiCo successfully appealed this decision at first instance, arguing that the product was marketed as an effervescent drinkable preparation sold in supermarkets, not just pharmacies.
On appeal, the Athens Administrative Court of Appeals overturned PepsiCo’s victory, relying heavily on two factors: the heightened attention of consumers and linguistic meaning. The court noted that "PEPSI" derives from the Greek word pepsi, meaning "digestion." Since the contested goods were for digestive disorders, the mark had descriptive relevance in Greek. Furthermore, the court emphasized that even for OTC products sold in supermarkets, consumers exhibit high attention due to the health implications of the product.
In a separate but related case involving the word mark "PEPSIFALK," PepsiCo’s opposition failed for similar reasons. The courts determined that because the relevant public pays close attention to pharmaceuticals and the term has a direct descriptive meaning in Greek, there was no likelihood of confusion or unfair advantage. This decision effectively limits the scope of protection for reputed marks when they intersect with pharma goods in markets where the mark has descriptive significance.
The Implications for Brand Strategy
The consistent application of the "heightened level of attention" principle across different jurisdictions creates a significant challenge for pharmaceutical companies. The logic is circular: consumers are assumed to be vigilant, so they will not be confused by similar marks, therefore, the brand requires less protection. However, this presumption lacks empirical evidence and does not account for the reality of consumer behavior in fast-paced retail environments.
For businesses, relying solely on trademark law to protect pharma-related brands is risky. The legal system’s assumption that consumers are always cautious creates a blind spot. A brand may look distinct in a legal analysis based on "careful consumption" but may appear identical to a hurried shopper selecting an OTC remedy at a pharmacy counter.
Furthermore, the difficulty in enforcing rights against reputed marks in the pharma sector is exacerbated by local linguistic contexts. If a brand name has a descriptive meaning in a key market language, its protection against similar pharma marks may be significantly weakened. This forces companies to navigate a landscape where their global brand equity is diminished by local legal interpretations of consumer attention.
Monitoring and Mitigation Strategies
Given these legal hurdles, proactive trademark monitoring becomes critical for pharmaceutical brands. Passive reliance on the presumption of consumer vigilance is insufficient. Companies must take the following steps:
- Conduct Comprehensive Searches: Before launching a new pharma-related brand, conduct deep searches in all target markets, paying close attention to local linguistic meanings and existing Class 5 registrations that might be similar but currently coexist due to the "heightened attention" doctrine.
- Monitor Closely for Similar Marks: Implement robust monitoring systems not just for exact matches, but for phonetically similar marks that could slip through the net of visual comparison. The risk lies in the gap between legal presumption and actual consumer confusion.
- Use Defensive Strategies: Consider registering trademarks in related classes (such as Class 35 for advertising or Class 44 for medical services) to create additional layers of protection that are less subject to the "product-based" confusion analysis.
- Focus on Distinctive Branding: Ensure that pharma brand names are inherently distinctive and avoid any terms that could be interpreted as descriptive of health benefits in local languages. This reduces the risk of marks being invalidated or limited based on descriptiveness.
The legal framework surrounding pharmaceutical trademarks is designed to prioritize public safety but often leaves brands vulnerable to incremental encroachment by competitors. Understanding the limitations of the "heightened level of attention" principle is essential for developing a realistic and effective intellectual property strategy. Companies must look beyond court presumptions and address the actual behaviors of consumers in the marketplace.